EUVIMEDEUVIMED entdecken
Multizentrische Studie

Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.

Giulia Orsi, Catia Carconi, Paola Ghiorzo, Paola Carrera, Lorenza Pastorino, Silvia Presi, Marta Chiaravalli, Elena Barbieri, Guido Giordano, Stefania Sciallero, Alberto Puccini, Lisa Salvatore und 14 weitere

European Journal of Cancer · 2024-09 · 208 · 114226

DOI: 10.1016/j.ejca.2024.114226 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Giulia Orsi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salu…. Hauptthemen laut MEDLINE: Germ-Line Mutation, Pancreatic Neoplasms, Genetic Predisposition to Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: Germline BRCA1-2 test is routinely recommended in Pancreatic Cancer (PC) patients, due to its clinical-epidemiological relevance. Data on the prevalence of germline pathogenic variants (gPV) in other cancer predisposition and DNA Damage Repair (DDR) system-related genes in unselected PC cases are sparce in Italy. We assessed this prevalence in a multicentre cohort, to derive recommendations for PC patients. METHODS: Clinical data of 1200 consecutive PC patients, of any age and stage, tested with a multigene germline panel were collected. A descriptive analysis of gPV frequency and clinical variables was performed both in 1092 patients tested for an 18 genes core-panel (CP-18 cohort) and in 869 patients screened only for CDKN2A. RESULTS: 11.5 % (126/1092) of CP-18 cohort patients harbored a gPV in ≥ 1 gene. Highest gPV frequencies were detected in ATM (3.1 %), BRCA2 (2.9 %), BRCA1 (1.6 %), CHEK2 (1.1 %). Patients harboring any CP-18 gene and BRCA1-2 gPV were younger and with a higher rate of personal (PH) or family history (FH) of cancer when compared to no gPV patients. The risk of having a gPV was ≥ 7 % in all subgroups of patients, including those aged > 73, with tumor stage I-III and negative FH/PH. CDKN2A gPV were detected in 2.6 % (23/869) of patients. CONCLUSIONS: A remarkable prevalence of gPV in cancer predisposition and DDR genes is reported in this large multicentre cohort of consecutive and unselected PC patients. Therefore, we recommend multigene germline testing (at least including BRCA1-2, ATM, CDKN2A, PALB2) for all PC patients, irrespective of age, stage, PH/FH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationPancreatic NeoplasmsGenetic Predisposition to DiseaseHumansMaleFemaleItalyMiddle AgedAgedAdultAged, 80 and overAtaxia Telangiectasia Mutated ProteinsCheckpoint Kinase 2

Stichwörter der Autor:innen

ATMBRCACancer predisposition genesDNA damage repairGermline pathogenic variantPancreatic cancer

Substanzen

ATM protein, humanAtaxia Telangiectasia Mutated ProteinsCHEK2 protein, humanCheckpoint Kinase 2

Autor:innen und Institutionen

  • Department of Medical Oncology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy; Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Unit of Genomics for Human Disease Diagnosis, Laboratory of Clinical Genomics, IRCCS San Raffaele Scientific Institute, Milan, Italy; Laboratory of Clinical Molecular Genetics, IRCCS San Raffaele Scientific Institute, M…
  • Oncologia medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
  • SS Genetica Oncologica, SC Oncologia Medica, AOU Policlinico, Modena, Italy.
  • Unit of Medical Oncology and Biomolecular Therapy, Policlinico Ospedaliero-Universitario, Foggia, Italy; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Förderung

  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Orsi, G., Carconi, C., Ghiorzo, P., Carrera, P., Pastorino, L., Presi, S., Chiaravalli, M., Barbieri, E., Giordano, G., Sciallero, S., Puccini, A., Salvatore, L., Cortesi, L., Macchini, M., Natalicchio, M. I., Allavena, E., Pirrone, C., Archibugi, L., Dalmasso, B., …, & Reni, M. (2024). Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. European Journal of Cancer, 208, 114226. https://doi.org/10.1016/j.ejca.2024.114226

Vancouver

Orsi G, Carconi C, Ghiorzo P, Carrera P, Pastorino L, Presi S, et al. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. European Journal of Cancer. 2024;208:114226. doi:10.1016/j.ejca.2024.114226

BibTeX
@article{Orsi2024,
  author = {Orsi, Giulia and Carconi, Catia and Ghiorzo, Paola and Carrera, Paola and Pastorino, Lorenza and Presi, Silvia and Chiaravalli, Marta and Barbieri, Elena and Giordano, Guido and Sciallero, Stefania and Puccini, Alberto and Salvatore, Lisa and Cortesi, Laura and Macchini, Marina and Natalicchio, Maria Iole and Allavena, Eleonora and Pirrone, Chiara and Archibugi, Livia and Dalmasso, Bruna and Bruno, William and Tortora, Giampaolo and Landriscina, Matteo and Capurso, Gabriele and Cascinu, Stefano and Falconi, Massimo and Reni, Michele},
  title = {Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {208},
  pages = {114226},
  doi = {10.1016/j.ejca.2024.114226}
}
Kostenlos starten →